Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous, Non-squamous or Not Otherwise Specified NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

For full description, see clinicaltrials.gov, study #NCT03041181